[go: up one dir, main page]

ES2656762T3 - Método y composiciones para tratamiento del cáncer - Google Patents

Método y composiciones para tratamiento del cáncer Download PDF

Info

Publication number
ES2656762T3
ES2656762T3 ES09723788.7T ES09723788T ES2656762T3 ES 2656762 T3 ES2656762 T3 ES 2656762T3 ES 09723788 T ES09723788 T ES 09723788T ES 2656762 T3 ES2656762 T3 ES 2656762T3
Authority
ES
Spain
Prior art keywords
compositions
cancer treatment
composition
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09723788.7T
Other languages
English (en)
Inventor
Angelika Burger
Hans Hendriks
Bernardus Rademaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMINOX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMINOX Inc filed Critical KOMINOX Inc
Application granted granted Critical
Publication of ES2656762T3 publication Critical patent/ES2656762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un equipo para su uso en el tratamiento de cáncer pulmonar que comprende una primera composición que comprende una cantidad terapéuticamente eficaz de metaarsenito de sodio y una segunda composición que comprende una cantidad terapéuticamente eficaz de un agente citotóxico antineoplásico seleccionado del grupo que consiste en cisplatino, paclitaxel y docetaxel.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
Tabla 2. Valores del índice de combinación
Estirpe celular
IC DE50 IC DE75 IC DE90
A549
0,86 0,75 0,68
H460
0,33 0,16 0,09
Tabla 3. Valores individuales del índice de agente: células H460
µM
Metaarsenito sódico Cisplatino Metaarsenito sódico-Cisplatino
CI50
10 1 0,7
CI75
20 1,7 1
CI90
30 2,5 1,5
Tabla 4. Valores individuales del índice de agente: células A549
µM
Metaarsenito sódico Cisplatino Metaarsenito sódico-Cisplatino
CI50
13 1,5 0,457
CI75
19 2 0,7
CI90
17 4 1,1
10

Claims (1)

  1. imagen1
ES09723788.7T 2008-03-27 2009-03-24 Método y composiciones para tratamiento del cáncer Active ES2656762T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US408864 1989-09-05
US3998708P 2008-03-27 2008-03-27
US39987P 2008-03-27
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Publications (1)

Publication Number Publication Date
ES2656762T3 true ES2656762T3 (es) 2018-02-28

Family

ID=41114644

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09723788.7T Active ES2656762T3 (es) 2008-03-27 2009-03-24 Método y composiciones para tratamiento del cáncer

Country Status (20)

Country Link
US (2) US20090246291A1 (es)
EP (1) EP2268292B1 (es)
JP (2) JP5543956B2 (es)
KR (1) KR101634138B1 (es)
CN (2) CN102046187A (es)
AU (1) AU2009228378B2 (es)
BR (1) BRPI0909164A2 (es)
CA (1) CA2719766C (es)
CY (1) CY1120536T1 (es)
DK (1) DK2268292T3 (es)
ES (1) ES2656762T3 (es)
HU (1) HUE036609T2 (es)
LT (1) LT2268292T (es)
MX (1) MX2010010621A (es)
PL (1) PL2268292T3 (es)
PT (1) PT2268292T (es)
RU (1) RU2508116C2 (es)
SI (1) SI2268292T1 (es)
WO (1) WO2009120697A2 (es)
ZA (1) ZA201006988B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
WO2011031890A2 (en) * 2009-09-10 2011-03-17 Kominox Usa, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP6034288B2 (ja) * 2010-07-18 2016-11-30 ニーキ ファーマ インコーポレイテッド ルテニウム錯体を用いる併用療法
KR101806255B1 (ko) * 2010-08-24 2017-12-07 지티엑스, 인코포레이티드 암 치료용 화합물
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
CA2835631A1 (en) * 2011-05-12 2012-11-15 Board Of Regents, The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
MX384297B (es) * 2016-12-01 2025-03-14 Eupharma Pty Ltd Composiciones de arsénico.
CA3094115A1 (en) * 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
CA2481602C (en) * 2002-04-10 2011-06-21 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US7867492B2 (en) * 2007-10-12 2011-01-11 The John Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
RU2010143893A (ru) 2012-05-10
SI2268292T1 (en) 2018-03-30
CY1120536T1 (el) 2019-07-10
RU2508116C2 (ru) 2014-02-27
CN102046187A (zh) 2011-05-04
WO2009120697A3 (en) 2010-02-18
JP5543956B2 (ja) 2014-07-09
ZA201006988B (en) 2012-05-30
US20090246291A1 (en) 2009-10-01
US20180055812A1 (en) 2018-03-01
WO2009120697A2 (en) 2009-10-01
WO2009120697A4 (en) 2010-04-15
CA2719766A1 (en) 2009-10-01
PL2268292T3 (pl) 2018-06-29
MX2010010621A (es) 2011-04-05
PT2268292T (pt) 2018-02-19
LT2268292T (lt) 2018-03-26
HUE036609T2 (hu) 2018-07-30
EP2268292A4 (en) 2011-05-11
KR20110009664A (ko) 2011-01-28
AU2009228378A1 (en) 2009-10-01
EP2268292A2 (en) 2011-01-05
EP2268292B1 (en) 2017-12-27
CN104997808A (zh) 2015-10-28
BRPI0909164A2 (pt) 2016-06-21
DK2268292T3 (en) 2018-03-12
JP2014101387A (ja) 2014-06-05
KR101634138B1 (ko) 2016-06-28
AU2009228378B2 (en) 2014-07-17
JP2011515481A (ja) 2011-05-19
CA2719766C (en) 2017-10-31

Similar Documents

Publication Publication Date Title
ES2656762T3 (es) Método y composiciones para tratamiento del cáncer
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
CO6531430A2 (es) Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2011001853A1 (es) Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras.
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
CL2008002982A1 (es) Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata.
UY31724A (es) " compuestos heterocíclicos novedosos y usos de los mismos"
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CY1110813T1 (el) Χημικες ενωσεις
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
DOP2010000323A (es) Pirimidin-5-carboxamidas sustituidas 281
UY30759A1 (es) Compuestos quimicos
JP2008535927A5 (es)
ECSP055618A (es) Terapia de combinacion para enfermedades hiperproliferativas
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
MX2019007010A (es) Compuestos y composiciones para el tratamiento del cancer.
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones